[{"orgOrder":0,"company":"NanoMab Technology","sponsor":"OncoBeta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2020","type":"Agreement","leadProduct":"188-Re","moa":"Beta-radiation","graph1":"Oncology","graph2":"Undisclosed","graph3":"NanoMab Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoMab Technology \/ NanoMab Technology","highestDevelopmentStatusID":"1","companyTruncated":"NanoMab Technology \/ NanoMab Technology"},{"orgOrder":0,"company":"NanoMab Technology","sponsor":"NanoMab Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"99m-Tc NM-02","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"NanoMab Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanoMab Technology \/ NanoMab Technology","highestDevelopmentStatusID":"6","companyTruncated":"NanoMab Technology \/ NanoMab Technology"},{"orgOrder":0,"company":"NanoMab Technology","sponsor":"NanoMab Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"99m-Tc NM-02","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"NanoMab Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanoMab Technology \/ NanoMab Technology","highestDevelopmentStatusID":"6","companyTruncated":"NanoMab Technology \/ NanoMab Technology"},{"orgOrder":0,"company":"NanoMab Technology","sponsor":"NanoMab Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"68-Ga PSMA","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"NanoMab Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NanoMab Technology \/ NanoMab Technology","highestDevelopmentStatusID":"6","companyTruncated":"NanoMab Technology \/ NanoMab Technology"},{"orgOrder":0,"company":"NanoMab Technology","sponsor":"University Hospital Aachen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"NM-02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NanoMab Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoMab Technology \/ University Hospital Aachen","highestDevelopmentStatusID":"6","companyTruncated":"NanoMab Technology \/ University Hospital Aachen"}]